Clinical Trials · NCT06511791
An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.
- Phase
- Phase 1
- Recruitment status
- Terminated
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 106
- Start date
- Jul 2024
- Locations
- 15 sites, 5 countries
- Primary endpoint
- Number of good-quality blastocysts